MEDIUMRegulatoryTier 1
Sunny Pharmtech, Inc. Issues Voluntary Nationwide Recall of Cyclophosphamide for Injection, USP to the User Level Due to the Presence of Particulate Matter
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Dental practices that administer cyclophosphamide for oral-cancer or transplant patients must verify lot numbers immediately; the recall affects two vial sizes and could interrupt oncology care or necessitate urgent patient rescheduling.
Key points
- Three lots of 1 g and 2 g cyclophosphamide vials were pulled nationwide after steel particulate matter was detected.
- No adverse events have been reported so far, but the recall is being executed at the user level.
- Clinics using cyclophosphamide for oral-cancer chemotherapy or pre-transplant conditioning should quarantine affected stock and contact their supplier for replacement product.
- DSOs or hospital-based dental services may need to coordinate with oncology or pharmacy teams to avoid treatment delays.
Who should care
OwnerSpecialistDSO
Read the original on FDA Recalls
Full reporting and any paywall content live on fda.gov. We summarize and score; we do not republish.